Caricamento...
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada
BACKGROUND: In Canada and elsewhere, pazopanib and sunitinib—tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors—are recommended as first-line treatment for patients with metastatic renal cell carcinoma (mrcc). A large randomized noninferiority trial of pazopanib ve...
Salvato in:
| Pubblicato in: | Curr Oncol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Multimed Inc.
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4974040/ https://ncbi.nlm.nih.gov/pubmed/27536183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.23.2244 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|